Evidence map›Paper›PMID 26819954›Full record

Trial reportBioMed research international2015

Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.

Oleg Blyuss, Alex Gentry-Maharaj, Evangelia-Orania Fourkala, Andy Ryan, Alexey Zaikin, Usha Menon, Ian Jacobs, John F Timms

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Molecular Management of High-Grade Serous Ovarian Carcinoma.International journal of molecular sciences · 2022
    Review
  5. Article
  6. Review
  7. Biomarkers and Strategies for Early Detection of Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Oleg BlyussWomen's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
Alex Gentry-MaharajWomen's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
Evangelia-Orania FourkalaWomen's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
Andy RyanWomen's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
Alexey ZaikinWomen's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
Usha MenonWomen's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
Ian JacobsWomen's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK; University of New South Wales, Sydney, NSW 2052, Australia.
John F TimmsWomen's Cancer, Institute for Women's Health, University College London, Gower Street, London WC1E 6BT, UK.
University College London · GBUNSW Sydney · AU

Funding

Cancer Research UK 12677Cancer Research UK A12677Medical Research Council G0801228
6 · The paper itself

Abstract

Early detection of ovarian cancer through screening may have impact on mortality from the disease. Approaches based on CA125 cut-off have not been effective. Longitudinal algorithms such as the Risk of Ovarian Cancer Algorithm (ROCA) to interpret CA125 have been shown to have higher sensitivity and specificity than a single cut-off. The aim of this study was to investigate whether other ovarian cancer-related biomarkers, Human Epididymis 4 (HE4), glycodelin, mesothelin, matrix metalloproteinase 7 (MMP7), and cytokeratin 19 fragment (CYFRA 21-1), could improve the performance of CA125 in detecting ovarian cancer earlier. Serum samples (single and serial) predating diagnosis from 47 women taking part in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) who went on to develop primary invasive ovarian, fallopian tube, or peritoneal cancer (index cancer) (170 samples) and 179 matched controls (893 samples) were included in the study. A multiplex immunobased assay platform (Becton Dickinson) allowing simultaneous measurement of the six serum markers was used. The area under the ROC curve for the panel of three biomarkers (CA125, HE4, and glycodelin) was higher than for CA125 alone for all analysed time groups, indicating that these markers can improve on sensitivity of CA125 alone for ovarian cancer detection.

Indexed as

AlgorithmsAdultBiomarkers, TumorDatasets as TopicFemaleHumansMiddle AgedNeoplasm ProteinsOvarian NeoplasmsRadiographyBiomarkers, TumorNeoplasm Proteins

Identifiers

PMID26819954
PMCPMC4706857
OpenAlexW2285870893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.